Category: Press

MED.Innov' : Le podcast-vidéo par Marianne Lahana avec Juliette Renauld

Cancer diagnosis, AI and regulatory issues

We are delighted to share with you the intervention of Juliette Renauld, founder and CEO of Genexpath, in the first episode of the podcast M ED.Innov’created by Marianne Lahanahealth law attorney at Phusis Avocats.

In this fascinating exchange, Juliette Renauld looks back on the progress of Genexpath in the field of cancer diagnosis and on the regulatory and ethical challenges linked to health innovations.

On the program for this episode:

✅L’innovation au service du diagnostic
Genexpath développe des tests de diagnostic de nouvelle génération. Ces solutions améliorent la caractérisation des lymphomes non hodgkiniens et des sarcomes. Elles allient biologie moléculaire, séquençage de nouvelle génération (NGS) et intelligence artificielle.

✅ The challenges of CE marking
CE marking is essential for marketing a medical device in Europe. Juliette Renauld shares her experience and the key steps in this regulatory process.

✅ AI in health: opportunities and limits
Artificial intelligence is transforming medical diagnosis. However, its use raises ethical and regulatory questions. Protecting patient data remains a priority.

✅ Reimbursement of innovative medical devices
After CE marking, access to reimbursement is another challenge. Marianne Lahana explains the steps to follow and the impact of the Reference Framework for Non-Nomenclature Investigations (RIHN).

🎧 Listen to the episode now on INVIVOX

Thanks to Marianne Lahana for this enriching exchange and Hub FranceIA for this partnership which highlights technological advances in the service of health.

To know more about Genexpath and our innovations in oncological diagnosis, visit 🌐 www.genexpath.com.

Étiquettes Issues, Genexpath, History, Podcast

Laurine Bacquet lors du Congrès SFMPP 2024, Genexpath

From October 9 to 11, 2024, the Congrès de la Société Française de Médecine Prédictive et Personnalisée (SFMPP) brought together researchers, clinicians and innovative companies to discuss advances in oncogenomics, genomics and artificial intelligence.

As part of the session “START-UP PITCHS: Innovation in predictive and personalized medicine”, Genexpath presented its work and innovative solutions to improve the diagnosis of pathologies using genomics.

During this intervention, we addressed the following topic:

📌 “Custom RT-MLPSeq: how to characterize pathologies using a simple, turnkey expression signature.”

Diagnostic tools based on gene expression analysis offer promising prospects for better understanding and characterizing many pathologies, particularly in oncology. Genexpath is developing customized solutions that leverage RT-MLPSeq for rapid and accurate analysis of expression

Watch the replay of our intervention

We invite you to discover how Genexpath uses innovation in genomics to deliver more precise and personalized diagnosis.

▶️ Access the replay here

To know more about Genexpath and our advances in genomic medicine, visit our site: 🌐 www.genexpath.com

Étiquettes Congress, Presentation, Replay

Photo Juliette Renauld pour le podcast de Hit West, Ouest France

Juliette Renauld, CEO of Genexpath, guest on the Orange Women Entrepreneurs podcast

On June 14, 2023, Juliette Renauld, founder and director of Genexpath, had the honor of participating in the podcast of Orange Women Entrepreneurs, hosted by Stéphanie Necca and Diane Berger, and broadcast on Hit West with the collaboration of Ouest FranceThis podcast highlights the journeys of women engaged in innovation and entrepreneurship, sharing their challenges, their vision and their impact in their respective fields.

During this fascinating discussion, Juliette Renauld discussed her entrepreneurial journey and Genexpath's mission: to develop next-generation diagnostic tests to better characterize certain complex cancers, particularly non-Hodgkin's lymphomas and sarcomas. By providing physicians with more precise diagnostic tools, Genexpath contributes to better classification of cancers, which helps direct patients toward more appropriate and effective treatments.

Juliette also shared the challenges encountered in the creation and development of Genexpath, between scientific advances and regulatory requirements, as well as her commitment to innovation in the field of medical diagnostic

His participation in this podcast is a unique opportunity to learn more about the importance of diagnosis in the fight against cancer and how biotechnology can transform patient care.

Discover his inspiring story now and dive into the story of Genexpath by listening to the full podcast.

🎧 Listen to the full podcast here

Étiquettes Genexpath, History, Podcast

Genexpath Etats-unis présentation solutions caractérisation cancer

Genexpath was one of 11 companies to travel to the USA to discover the American market. Alongside regional elected officials and tourism representatives, a number of Normandy-based tech and medtech companies were present.

This visit was an opportunity for the Region's elected officials to promote the economic attractiveness of Normandy to American companies.

Juliette Renauld et Pierre-Julien Viailly lors du Congès SFMPP 2022, Genexpath

From October 5 to 7, 2022, the Congrès de la Société Française de Médecine Prédictive et Personnalisée (SFMPP) brought together experts, researchers and innovative companies around the latest advances in genomics and oncogenomics. Genexpath had the opportunity to present its work as part of the session dedicated to French start-ups and innovation in genomic medicine.

During this presentation, we addressed the theme:

📌 “Optimizing tumor characterization: a new diagnostic approach for sarcomas and lymphomas.”

Sarcomas and lymphomas are particularly complex cancers to diagnose. Accurately classifying them is essential for providing patients with appropriate treatment. Genexpath is developing next-generation diagnostic tests that enable more detailed analysis of these tumors, thereby providing better care.

Watch the replay of our intervention

We invite you to relive our presentation and discover how innovation in oncogenomics contributes to more precise and personalized medicine.

▶️ Access the replay here

To know more about Genexpath and our advances in genomic medicine, visit our site: 🌐 www.genexpath.com

Étiquettes Congress, Presentation, Replay

Prix 10.000 startups 2022

Back for a 10th event season, the 10,000 Startups to Change the World Prize, organized by La Tribune, rewarded six startups in Nantes

Back for a 10th event season, the 10,000 Startups to Change the World Prize, organized by La Tribune, rewarded six startups in Nantes from the Great West, including Brittany, Normandy, Pays-de-la-Loire and Center -Val-de-Loire: Equium, Thrasos, Pennylane, Wello, Genexpath and Taxirail. Will one of them leave, in addition, with a national grand prize? Answer on March 28 on the stage of the Grand Rex in Paris.

latribune.fr article

Commercialisation kit de diagnostic cancer

Un new start-up is born in Rouen : Genexpath

Born in November 2020, supported by Becquerel and Normandie Valorisation, it produces and markets diagnostic kits for lymphomas and sarcomas.

paris-normandie.fr article

Juliette Renauld, CEO

Created in November 2020, the start-up Genexpath is in the industrialization phase of diagnostic kits for certain cancers. Juliette Renauld, the manager, hopes to be able to market them at the end of the spring.

In the premises of the Genexpath start-up, near the Jardin des Plantes in Rouen, the boxes bear witness to the recent installation of Juliette Renauld and her team. The young company, created in November 2020 and incubated by Normandie Incubation, develops diagnostic kits for certain cancers, particularly lymphomas (tumors of the lymphatic system) and sarcomas (rare cancer of soft tissues, bones and cartilages, which affects many children).

gazettenormandie.fr article

Directrice genexpath et collaborateur dans les locaux genexpath

Backed by the Henri-Becquerel regional cancer center in Rouen, the young start-up Genexpath born in November 2020 has already designed, manufactured and marketed two diagnostic kits for lymphoma and sarcoma cancers.

Lire l’article sur ouest-france.fr

Genexpath logo png

Genexpath will develop, manufacture and market kits for lymphomas and sarcomas. It was created in Normandy and is based in Rouen.

Genepath is born

Genexpath will develop, manufacture and market kits for lymphomas and sarcomas. It was created in Normandy and is based in Rouen.

The Henri Becquerel Center research team led by Professor Fabrice Jardin has been working for several years in collaboration with other Normandy establishments to develop products to classify lymphomas and detect fusion genes in sarcomas. Genexpath is the logical continuation of this work that the teams wanted to see offered to healthcare centers to facilitate and make reliable diagnoses at the best price.

The Henri Becquerel Center, which is one of the 18 French Cancer Centers, has a triple mission of care, research and teaching. These first two missions are in perfect harmony with the Genexpath project which will make the research carried out within the center accessible. The Center Henri Becquerel is also a shareholder of Genexpath.

Normandie Valorisation, which brings together under its banner all the establishments and organizations involved in the activities of Norman research laboratories, has worked to enable the transfer of technology to Genexpath. She also became a shareholder.

Several researchers have also joined the adventure and as shareholders and/or stakeholders in the work of the company.

Genexpath is currently working to obtain CE-IVD marking for its products. The company will also market the GenerateReports software, also developed within the Henri Becquerel Center and allowing the analysis of raw sequencing data.

About Normandie Valorisation

Component fully integrated into Normandy University, NV has a multidisciplinary team of 23 professionals and a fund of more than €6 million for three years. NV brings its expertise in technology scouting, intellectual property, and licensing to promote the creation of a complete value chain in Normandy. With Normandie Valorisation, the innovations of the research laboratories of Normandy establishments go from the laboratory bench to the real world by becoming products or services useful to everyone, with a real impact on the territory.

About the Henri Becquerel Center

The Center is the bearer of a model based on the multidisciplinarity specific to the Cancer Centers, and tends towards personalized medicine, patient follow-up is provided by a medical team made up of different specialists (surgeon, radiotherapist, oncologist, etc.) supported by paramedics. It is a collective work for the benefit of the patient. 845 employees (including 99 doctors, university professors and researchers) serve nearly 25,200 patients per year.

Press Contact

GENEXPATH Juliette Renauld CEO Tel. 06 63 23 95 26 (Email jrenauld@www.genexpath.com)